← Oncology Approval Tracker

FDA DECISION ·

Ennumo

pegfilgrastim-pccg · Accord BioPharma

Biosimilar approvalBiosimilarChemotherapy-associated neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Neulasta biosimilar for lowering infection risk manifested by febrile neutropenia in patients with nonmyeloid cancers receiving myelosuppressive anticancer drugs associated with a clinically significant risk of febrile neutropenia.

LAMPGEN ANALYSIS

Why it matters

This adds a supportive-care option for an established growth-factor use. Site-level sourcing and coverage affect whether another approved option improves access.

What research teams should watch

Coordinate injection timing with chemotherapy and keep the actual product documented. Verify the device and presentation before assuming workflow equivalence.

PRIMARY RECORDS

Sources